Our in vivo results reveal that the FSA and FSA-Fmed tumor models are sensitive to PD-1 ICB monotherapy, but limited synergy was achieved by combining ICB with FAP-targeted RLT. This evidence concerns the gene PDCD1 and neoplasm.